“Phosphoproteomics predict response to midostaurin plus chemotherapy in independent cohorts of FLT3-mutated acute myeloid leukaemia”
- eBioMedicine (Lancet) 2024 GO TO SOURCE
“Multi-drug algorithm to accurately predict best first-line treatments in newly-diagnosed acute myeloid leukemia (AML)”
- American Society of Clinical Oncology 2024 GO TO SOURCE
“Identification of a predictive phosphoproteomic signature of response to atezolizumab and bevacizumab (AB) in patients with advanced hepatocellular carcinoma (aHCC)”
- American Society of Clinical Oncology 2024 GO TO SOURCE
“PiQuant: Software for Rapid and Accurate Quantification of Mass Spectrometry-based Proteomics Data”
- American Society of Mass Spectrometry 2024 GO TO SOURCE
“Phosphoproteomics predict response to Venetoclax plus Azacitidine in Acute Myeloid Leukemia patients”
- American Society of Mass Spectrometry 2024 GO TO SOURCE
“Reproducibility Analysis of Clinically-relevant Targets Identifies Durable Phosphopeptide Ions”
- American Society of Mass Spectrometry 2024 GO TO SOURCE
“Comprehensive Profiling of Data Acquisition Strategies to Optimize Clinically-feasible Approaches for Monitoring Predictive Phosphorylation Markers”
- American Society of Mass Spectrometry 2024 GO TO SOURCE
“Benchmarking machine learning strategies for phosphoproteomic data in clear cell renal carcinoma diagnosis and staging”
- American Society of Mass Spectrometry 2024 GO TO SOURCE
“A Comprehensive Analysis Pipeline for Phosphoproteomic Biomarker Discovery”
- American Society of Mass Spectrometry 2024 GO TO SOURCE
“Phosphoproteomics accurately predicts responses to midostaurin plus chemotherapy in two independent cohorts of FLT3 mutant-positive acute myeloid leukaemia”
- European Hematology Association 2023 GO TO SOURCE
“Identification of novel phosphoproteomic biomarkers in patients with advanced hepatocellular carcinoma (HCC)”
- American Society of Clinical Oncology 2023 GO TO SOURCE
“A persistent neutrophil-associated immune signature characterizes post-COVID-19 pulmonary sequelae”
- Science Translational Medicine 2022 GO TO SOURCE
“KScan: personalizing medicine with phosphoproteomics”
- Nature Article 2022 GO TO SOURCE
“Proteomics and Phospho-Proteomics Reveal Predictive Signatures of Response and Mechanisms of Resistance to Midostaurin Plus Chemotherapy in FLT3 Mutant Positive Acute Myeloid Leukemia”
- American Society of Hematology 2021 GO TO SOURCE
“Precision phosphoproteomic analysis in Chr22q11.2 amplified NSCLC cells reveals distinct signaling corruption and response to Aurora kinase B inhibition”
- American Association for Cancer Research 2021 GO TO SOURCE
“Predictive phosphoproteomic signatures for midostaurin plus chemotherapy response in FLT3 mutant positive acute myeloid leukaemia”
- American Society of Clinical Oncology 2021 GO TO SOURCE
“Computational Analysis of Cholangiocarcinoma Phosphoproteomes Identifies Patient-Specific Drug Targets”
- Cancer Research 2021 GO TO SOURCE
“Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways”
- iScience 2021 GO TO SOURCE
“Reconstructing kinase network topologies from phosphoproteomics data reveals cancer-associated rewiring”
- Nature Biotechnology 2020 GO TO SOURCE
“Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells”
- Leukemia 2018 GO TO SOURCE
“Kinase activity ranking using phosphoproteomics data (KARP) quantifies the contribution of protein kinases to the regulation of cell viability”
- Molecular and Cellular Proteomics 2017 GO TO SOURCE
“Empirical inference of circuitry and plasticity in a kinase signaling network”
- Proc Natl Acad Sci USA 2015 GO TO SOURCE
“Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells”
- Science Signaling 2013 GO TO SOURCE